Daily Respiratory Research Analysis
Three standout studies advance respiratory medicine across bench-to-bedside: a rationally engineered covalent ACE2 decoy receptor shows broad neutralization potential against SARS-CoV-2 variants; a circulating two-miRNA signature (with lymphocyte count) enables early diagnosis and risk stratification of checkpoint inhibitor-related pneumonitis; and a nationwide propensity-matched analysis links preoperative GLP-1 receptor agonist use to markedly fewer perioperative respiratory complications.
Summary
Three standout studies advance respiratory medicine across bench-to-bedside: a rationally engineered covalent ACE2 decoy receptor shows broad neutralization potential against SARS-CoV-2 variants; a circulating two-miRNA signature (with lymphocyte count) enables early diagnosis and risk stratification of checkpoint inhibitor-related pneumonitis; and a nationwide propensity-matched analysis links preoperative GLP-1 receptor agonist use to markedly fewer perioperative respiratory complications.
Research Themes
- Engineered decoy receptors and covalent protein therapeutics for respiratory viruses
- Noninvasive biomarkers for immune-related pneumonitis diagnosis and prognosis
- Perioperative medication safety and respiratory complication prevention
Selected Articles
1. Rational design of a covalent ACE2 decoy receptor that broadly neutralizes SARS-CoV-2 variants.
Using non-canonical amino acid chemistry, the authors engineered ACE2-Fc decoys (E23FSY, T27FSY) that covalently capture a conserved RBD residue (Y473), maintaining binding to Omicron BA.5 and markedly enhancing pseudovirus neutralization over noncovalent ACE2-Fc. This provides a blueprint for escape-resistant, broad-spectrum antiviral biologics.
Impact: Introduces a mechanistically novel, covalent decoy receptor that targets an evolutionarily constrained site, overcoming variant escape—a potential paradigm for resilient antivirals.
Clinical Implications: While preclinical, covalent ACE2 decoys could evolve into pan-variant therapeutics for COVID-19 and future coronaviruses. Translation will require in vivo efficacy, safety, and delivery/PK studies.
Key Findings
- Identified RBD tyrosine 473 (Y473) as a conserved, functionally constrained covalent target.
- Engineered ACE2-Fc (E23FSY, T27FSY) formed specific, efficient covalent bonds with RBD Y473.
- Covalent capture was retained against Omicron BA.5 RBD.
- Pseudovirus neutralization potency was markedly enhanced vs. non-covalent ACE2-Fc for D614G and Omicron variants.
Methodological Strengths
- Rational target selection integrating structural data and functional genomics to minimize escape risk.
- Use of non-canonical amino acid FSY enabling site-specific covalent capture and robust pseudovirus validation across variants.
Limitations
- Preclinical in vitro data; no in vivo efficacy or safety yet.
- Potential immunogenicity and manufacturability of FSY-containing biologics remain to be addressed.
Future Directions: Evaluate in vivo efficacy in animal models of SARS-CoV-2, assess immunogenicity, PK/PD, and delivery; expand covalent decoy paradigm to other conserved viral-host interfaces.
The ongoing evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the emergence of variants that evade existing vaccines and antibody therapies necessitate novel, potent, and broad-spectrum antiviral strategies. Enhancing therapeutic proteins with additional covalent binding capabilities, such as minibinders and nanobodies, reportedly potentiates their antiviral efficacy by irreversibly capturing the viral cell-entry protein. However, viral mutations that interfere with covalent bonding or reduce viral affinity with therapeutic proteins might compromise the efficacy of this strategy. Therefore, in this study, we aimed to develop a broadly neutralizing covalent angiotensin-converting enzyme 2-Fc (ACE2-Fc) decoy using a rational design strategy that integrates functional genomics with structural information. Using this approach, we targeted a highly conserved and functionally constrained residue on the viral receptor-binding domain (RBD) and identified tyrosine 473 (Y473) as an optimal target. We engineered ACE2-Fc constructs by replacing glutamate 23 (E23) and threonine 27 (T27) with the non-canonical amino acid-fluorosulfate-L-tyrosine (FSY), generating E23FSY and T27FSY constructs. These constructs formed a specific and efficient covalent bond with Y473 of the RBD. Notably, this covalent capture was retained against the highly mutated Omicron BA.5 RBD. In pseudovirus neutralization assays, both E23FSY and T27FSY exhibited markedly enhanced potency against both wild-type-like (D614G) and Omicron variants compared to their non-covalent counterparts. These results demonstrate that using an inherently escape-resistant decoy receptor to covalently target evolutionarily constrained residues on the viral RBD is a highly efficient strategy for creating potent, broad-spectrum covalent inhibitors against rapidly evolving viruses such as SARS-CoV-2.
2. Novel circulating microRNA signature for early detection and prognostication of checkpoint inhibitor-related pneumonitis.
A two-miRNA circulating signature (miR-193a-5p in EVs/serum and miR-378a-3p in serum), augmented by lymphocyte count, discriminated CIP from ICI-treated controls and infectious pneumonia with AUCs up to 0.959, and stratified overall survival (HR 2.83). This noninvasive panel could support earlier, more accurate CIP diagnosis and risk stratification.
Impact: Provides validated, easily measurable biomarkers to distinguish CIP from infectious pneumonia—a major diagnostic challenge—and to predict outcomes.
Clinical Implications: Incorporating this miRNA panel (with lymphocyte count) could enable earlier steroid initiation for CIP, reduce misclassification as infection, and guide monitoring intensity.
Key Findings
- A circulating signature (EV miR-193a-5p, serum miR-193a-5p, serum miR-378a-3p) distinguished CIP with AUC 0.837–0.870 (validation/training).
- Adding lymphocyte count improved discrimination (AUC up to 0.932 overall; 0.946 vs ICI; 0.959 vs infectious pneumonia).
- The 3-miRNA panel independently predicted overall survival in CIP (HR 2.827; p=0.040).
Methodological Strengths
- Multi-stage development with discovery, training, and independent validation cohorts across serum and EV compartments.
- Head-to-head discrimination against key differentials (ICI without CIP and infectious pneumonia) with robust AUCs and Cox survival modeling.
Limitations
- Sample size is moderate and bi-center; broader, prospective multicenter validation is needed.
- Cut-offs and clinical workflows for real-world implementation require standardization.
Future Directions: Prospective, multicenter implementation studies to evaluate impact on time-to-diagnosis, steroid timing, outcomes, and integration into irAE care pathways.
BACKGROUND: Checkpoint inhibitor-related pneumonitis (CIP) represents a highly lethal immune-related adverse event. Early diagnosis of CIP is crucial for timely intervention and improved prognosis; however, the absence of precise and effective diagnostic techniques often leads to underdiagnosis and misdiagnosis. This study aims to identify microRNA (miRNA) features from serum and extracellular vesicles (EVs) for the early CIP detection and prognosis. METHODS: Small RNA sequencing identified candidate miRNAs in 27 serum-derived EV samples from persons with lung cancer and CIP (CIP group) and those without, including immunotherapy-treated persons with lung cancer without CIP (immune checkpoint inhibitor, ICI group) and patients with infectious pneumonia (PNE group). These miRNAs were validated in EV samples in a discovery cohort (n=48) using a quantitative reverse transcription-PCR (qRT-PCR). Diagnostic models for the biomarkers were developed using a training cohort (ICI:47, PNE:28, CIP:31) and validated in a separate validation cohort (ICI:32, PNE:19, CIP:21) using qRT-PCR in both EV and serum samples, and logistic regression. Using a Cox regression model, we built a prognostic risk stratification for patients with CIP based on three miRNAs. RESULTS: Sequencing analysis initially screened and identified 13 overexpressed miRNAs in patients with CIP. Subsequently, qRT-PCR demonstrated that three miRNAs (EVs miR-193a-5p, serum miR-193a-5p, and serum miR-378a-3p) effectively distinguished CIP from non-CIP individuals (training cohort: area under the curve (AUC)=0.870; validation cohort: AUC=0.837). Notably, this miRNA signature was equally robust in differentiating CIP from ICI (training cohort: AUC=0.823; validation cohort: AUC=0.845) and PNE groups (training cohort: AUC=0.892; validation cohort: AUC=0.907). Furthermore, when combined with lymphocyte levels, the miRNA signature significantly enhanced the overall diagnostic accuracy in distinguishing CIP from the non-CIP group (training cohort: AUC=0.900; validation cohort: AUC=0.932), and maintained its robustness in distinguishing CIP from the ICI group (training cohort: AUC=0.898; validation cohort: AUC=0.946) and the PNE group (training cohort: AUC=0.938; validation cohort: AUC=0.959). Additionally, the three-miRNA panel was independently and significantly associated with overall survival in patients with CIP (HR: 2.827; p=0.040). CONCLUSIONS: Our circulating miRNA-based signature represents a non-invasive and robust diagnostic tool for patients with CIP and could accurately predict their prognosis. This signature may facilitate early detection and personalized management of these patients.
3. Risk of perioperative cardiorespiratory complications and mortality associated with preoperative glucagon-like peptide-1 receptor agonist use in type 2 diabetes mellitus: a nationwide propensity-score matched study.
In 296,389 matched pairs of adults with type 2 diabetes, preoperative GLP-1 RA exposure was associated with substantially fewer 30-day postoperative respiratory complications (RR 0.26) and aspiration events (RR 0.31), consistent across long- and short-acting agents. Findings challenge assumptions of increased aspiration risk due to delayed gastric emptying.
Impact: A very large, contemporary, real-world analysis directly informs perioperative policy debates on holding vs continuing GLP-1 RAs and quantifies respiratory risk.
Clinical Implications: Supports reconsidering blanket preoperative discontinuation of GLP-1 RAs; individualized risk assessment is warranted given low absolute event rates and potential benefits.
Key Findings
- Preoperative GLP-1 RA use was associated with fewer 30-day postoperative respiratory complications (0.09% vs 0.34%; RR 0.26, 95% CI 0.22–0.29).
- Pulmonary aspiration risk was lower with GLP-1 RA exposure (0.01% vs 0.03%; RR 0.31, 95% CI 0.20–0.49).
- Associations were consistent for both long- and short-acting GLP-1 RAs.
Methodological Strengths
- Nationwide, very large propensity-score matched cohort minimizing confounding by indication.
- Consistent effects across GLP-1 RA subclasses and clinically adjudicated outcomes within 30 days.
Limitations
- Observational design with residual confounding; perioperative fasting protocols and mitigation measures were unknown.
- Very low absolute event rates may limit precision for subgroup analyses.
Future Directions: Prospective studies and pragmatic trials to confirm causality, define perioperative management algorithms, and identify subgroups benefiting from continuation vs holding.
BACKGROUND: The use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) has raised concerns about delayed gastric emptying, pulmonary aspiration, and respiratory complications. This study aimed to investigate the association between preoperative GLP-1 RA use and perioperative respiratory complications in type 2 diabetes mellitus. METHODS: We conducted a nationwide propensity-score matched cohort study using the TriNetX database to analyse adults with type 2 diabetes mellitus undergoing surgery in the USA from January 1, 2016, to December 31, 2024. The exposure of interest was use of GLP-1 RA (prescription within 90 days before surgery) compared with individuals not receiving GLP-1 RA. The primary outcome was postoperative respiratory complications within 30 days of surgery, including aspiration. RESULTS: After propensity matching in 296 389 matched pairs (mean [sd] age, 58 [12] yr; 57% female), 259/296 389 (0.09%) receiving GLP-1 RA before surgery had fewer respiratory complications, compared with 1017/296 389 (0.34%) individuals who were not prescribed GLP-1 RA (relative risk, 0.26 [95% confidence interval, 0.22-0.29]; P<0.0001). Pulmonary aspiration occurred in 24/296 389 (0.01%) individuals receiving GLP-1 RA, compared with 78/296 389 (0.03%) not receiving GLP-1 RA (relative risk, 0.31 [95% confidence interval, 0.20-0.49]; P<0.0001). Both long- and short-acting GLP-1 RA use was associated with fewer respiratory complications. CONCLUSIONS: Preoperative GLP-1 RA use was associated with reduced risks of perioperative respiratory complications in people with type 2 diabetes mellitus. These findings were observed in a real-world cohort, with uncertainty about whether measures were undertaken to reduce the risk of aspiration.